Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective
Journal of Psychopharmacology · 2023
DOI: 10.1177/02698811221140004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Psychopharmacology, 2023. Verfasst von Jack E Henningfield und 3 weiteren Autor:innen. Beteiligte Einrichtung: PinneyAssociates, Inc, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Hallucinogens, Substance-Related Disorders. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 55 Literaturangaben.
Abstract (Originalsprache)
Background
Psychedelics are an increasingly active area of research and pharmaceutical development. This includes abuse potential assessment to better understand their pharmacological mechanisms and effects and guide controlled substance regulation. Psychedelics pose challenges to abuse assessments to ensure valid, reliable, and generalizable outcomes and safe study conduct.
Findings
Key nonclinical techniques, for example, receptor binding and functional assays in vitro, and nonclinical physical dependence determinations, are easily adaptable to psychedelics. However, the entactogens (weak reinforcers) and hallucinogens (non-reinforcers) require more flexible approaches than typically recommended by regulatory agencies. Phase 1 pharmacokinetic/pharmacodynamic safety studies and Phases 2/3 efficacy/safety trials with systematic monitoring of abuse-related adverse events are readily applicable to psychedelics. Human abuse trials require modification because supratherapeutic doses may not be safe and procedures, for example, personal monitors to manage serious adverse events, might bias outcomes. Recommendations: Abuse-related studies for psychedelics requiring approval by Food and Drug Administration and other agencies should take into consideration existing knowledge that will vary from extensive, for example, psilocybin, to zero for novel hallucinogens and entactogens. Many abuse assessments can be reasonably applied to animals and humans without compromising scientific integrity. Modification of existing techniques and incorporating a broader range of nonclinical tests should ensure generalizable outcomes. Human abuse studies merit reconsideration and possible modification to ensure safety and validity for psychedelic drug evaluation. Other nonclinical and clinical methods can provide evaluations of the pharmacological equivalence of test drugs to known drugs of abuse to provide context to the abuse assessment and guide drug scheduling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PinneyAssociates, Inc, Bethesda, MD, USA.
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- DevelRx Ltd, BioCity, Nottingham, UK.
- Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.
ORCID-Profile: David J Heal, Sharon L Smith
Zitieren
APA
Henningfield, J. E., Ashworth, J., Heal, D. J., & Smith, S. L. (2023). Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221140004
Vancouver
Henningfield JE, Ashworth J, Heal DJ, Smith SL. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. Journal of Psychopharmacology. 2023. doi:10.1177/02698811221140004
BibTeX
@article{Henningfield2023,
author = {Henningfield, Jack E and Ashworth, Judy and Heal, David J and Smith, Sharon L},
title = {Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective},
journal = {Journal of Psychopharmacology},
year = {2023},
doi = {10.1177/02698811221140004}
}
EUVIMED